Physician profile
Po Chu
NPI 1720236813
$16,604.16
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.88 · 2020: $22.73 · 2021: $544 · 2022: $717 · 2023: $1,121 · 2024: $3,249 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,967 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Food and Beverage | $3,966.62 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,623.86 | 2023-2025 | Linzess, Creon, Rinvoq |
| Gilead Sciences, INC. | $1,069.67 | 2019-2025 | Vemlidy |
| Vivus LLC | $695.02 | 2021-2025 | Pancreaze |
| Esperion Therapeutics, INC. | $688.54 | 2021-2022 | |
| Janssen Biotech, INC. | $448.90 | 2022-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $283.42 | 2024-2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $244.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.63 | 2023-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $87.29 | 2023 | |
| Braintree Laboratories, INC. | $56.49 | 2021-2023 | Sutab |
| Merck Sharp & Dohme LLC | $54.36 | 2024 | Dificid, Lagevrio |
| Redhill Biopharma INC. | $37.43 | 2022 | |
| Celgene Corporation | $34.03 | 2021 | |
| Viiv Healthcare Company | $28.11 | 2023 | Dovato |
| Ardelyx, INC. | $22.33 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $22.23 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $21.79 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.71 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $17.65 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Po Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.